Acquisitions3 Jun 2025, 04:51 pm
Zydus Lifesciences to Acquire US Biologics Manufacturing Facilities of Agenus for $75 Million Upfront
AI Summary
Zydus Lifesciences Ltd, through its subsidiary Zydus Pharmaceuticals USA Inc., has entered into a definitive agreement to acquire two U.S. based biologics manufacturing facilities of Agenus Inc., USA and Agenus West LLC for an upfront consideration of $75 million. The acquisition will provide Zydus with advanced biologics manufacturing capabilities in California and enable it to expand its reach in the U.S. and globally. Upon closing of the transaction, Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products.
Key Highlights
- Zydus to acquire two U.S. based biologics manufacturing facilities of Agenus for $75 million upfront
- The acquisition will provide Zydus with advanced biologics manufacturing capabilities in California
- Zydus will become an exclusive contract manufacturer for Agenus upon closing of the transaction
- Zydus will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products
- The acquisition is subject to required filings / approvals under the applicable laws, including Hart-Scott-Rodino Anti-Trust Improvements Act, 1976 (USA) and Committee for Foreign Investment in the United States (CFIUS)